Recent advances in the development of melatonin MT1 and MT2 receptor agonists

Importance of the field: Increasing clinical evidences suggest that melatonin receptor agonists can represent a novel therapeutic approach for the treatment of sleep disturbances and depression. A variety of studies also revealed a role of melatonin and its receptors in different patho-physiological conditions. Due to the multiple effects of this hormone, the design of new agents able to interact selectively with melatonin receptors has become an area of great interest during the last decade. Areas covered in this review: An extensive inspection of patents and scientific literature about MT1 and MT2 melatonin receptor agonists reported from 1999 to early 2010. What the reader will gain: A comprehensive review of structures recently claimed as melatonin receptor agonists and a broad overview of structure–activity relationships for these ligands. Take home message: After 5 decades of research, the field of melatonin receptor agonists comprises a variety of chemical entities, belonging to structurally different classes. Patents filed since 1999 claim new melatonin receptor agonists, characterized either by improved pharmacokinetic or pharmacodynamic properties, compared to those of melatonin receptor agonists already approved for clinical uses. The results of preclinical studies on animal models show that melatonin receptor agonists can be considered promising agents for the treatment of CNS-related pathologies.

[1]  A. Lewy.  Circadian misalignment in mood disturbances , 2009, Current psychiatry reports.

[2]  G. Maestroni,et al.  Melatonin in rheumatoid arthritis: synovial macrophages show melatonin receptors. , 2002, Annals of the New York Academy of Sciences.

[3]  R. Ravid,et al.  Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease , 2005, Journal of pineal research.

[4]  Burkhard Poeggeler,et al.  Melatonin and Melatonergic Drugs on Sleep: Possible Mechanisms of Action , 2009, The International journal of neuroscience.

[5]  Yogesh K. Dwivedi,et al.  The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. , 2005, Brain research. Molecular brain research.

[6]  Silvia Rivara,et al.  Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. , 2008, Current topics in medicinal chemistry.

[7]  S. Reppert,et al.  The Mel1a melatonin receptor gene is expressed in human suprachiasmatic nuclei , 1996, Neuroreport.

[8]  D. Sugden,et al.  Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat , 2009, Neuroscience Letters.

[9]  M. Gillette,et al.  Suprachiasmatic nucleus: the brain's circadian clock. , 1999, Recent progress in hormone research.

[10]  R. Hardeland.  Investigational melatonin receptor agonists , 2010, Expert opinion on investigational drugs.

[11]  A. Tsotinis,et al.  Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles. , 2000, Journal of medicinal chemistry.

[12]  R. Nelson,et al.  Melatonin enhancement of splenocyte proliferation is attenuated by luzindole, a melatonin receptor antagonist. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[13]  D. Dawson,et al.  Melatonin agonists and insomnia , 2010, Expert review of neurotherapeutics.

[14]  Astrid A. Ortiz,et al.  Chronobiotic activity of N-[2-(2,7-dimethoxyfluoren-9-yl)ethyl]-propanamide. Synthesis and melatonergic pharmacology of fluoren-9-ylethyl amides. , 2004, Bioorganic & medicinal chemistry.

[15]  V. Gribkoff,et al.  Targeted Disruption of the Mouse Mel1b Melatonin Receptor , 2003, Molecular and Cellular Biology.

[16]  D. Steinhilber,et al.  Melatonin receptor ligands , 1999 .

[17]  M. Dubocovich,et al.  MT(2) melatonin receptors are present and functional in rat caudal artery. , 2002, The Journal of pharmacology and experimental therapeutics.

[18]  M. Dubocovich,et al.  Constitutively active melatonin MT(1) receptors in male rat caudal arteries. , 2002, European journal of pharmacology.

[19]  A. Wirz-Justice,et al.  Distribution of Melatonin MT1 Receptor Immunoreactivity in Human Retina , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[20]  D. Mayleben,et al.  The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. , 2005, The Journal of clinical psychiatry.

[21]  Prahlad T. Ram,et al.  Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells , 2004, Breast Cancer Research and Treatment.

[22]  D. Acuña-Castroviejo,et al.  Cellular mechanisms involved in the melatonin inhibition of HT‐29 human colon cancer cell proliferation in culture , 2007, Journal of pineal research.

[23]  Hsiao-Wen Lin,et al.  Effects of melatonin in experimental stroke models in acute, sub-acute, and chronic stages , 2009, Neuropsychiatric disease and treatment.

[24]  R. Reiter,et al.  Melatonin as a naturally occurring co‐substrate of quinone reductase‐2, the putative MT3 melatonin membrane receptor: hypothesis and significance , 2007, Journal of pineal research.

[25]  M. Mor,et al.  Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue. , 2006, Bioorganic & medicinal chemistry.

[26]  Sukru Oter,et al.  Melatonin: An Established Antioxidant Worthy of Use in Clinical Trials , 2009, Molecular medicine.

[27]  S. T. Inouye,et al.  Persistence of circadian rhythmicity in a mammalian hypothalamic "island" containing the suprachiasmatic nucleus. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Josep M. Guerrero,et al.  Membrane‐bound calmodulin in Xenopus laevis oocytes as a novel binding site for melatonin , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  Anna Wirz-Justice,et al.  Circadian Clues to Sleep Onset Mechanisms , 2001, Neuropsychopharmacology.

[30]  M. J. Jarzynka,et al.  Melatonin receptors and their regulation: biochemical and structural mechanisms. , 2003, Life sciences.

[31]  G. Maestroni,et al.  Melatonin in Rheumatoid Arthritis , 2002 .

[32]  M. Mor,et al.  N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. , 2007, Journal of medicinal chemistry.

[33]  İ. Solmaz,et al.  Antiepileptic activity of melatonin in guinea pigs with pentylenetetrazol-induced seizures , 2009, Neurological research.

[34]  Recent Advances in Melatonin Receptor Ligands , 2005, Archiv der Pharmazie.

[35]  A. Tsotinis,et al.  Synthesis and biological evaluation of new β,β′-disubstituted 6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl ethylamido melatoninergic ligands , 2003 .

[36]  F. Facchinetti,et al.  Effect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy , 2001, Clinical endocrinology.

[37]  G. Bubenik.  Gastrointestinal melatonin: localization, function, and clinical relevance. , 2002, Digestive diseases and sciences.

[38]  Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles. , 2000 .

[39]  J. Boutin,et al.  New selective ligands of human cloned melatonin MT1 and MT2 receptors , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[40]  V. Granados-Soto,et al.  Melatonin: a hormone that modulates pain. , 2009, Life sciences.

[41]  C. D. Mahle,et al.  Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. , 2004, Bioorganic & medicinal chemistry letters.

[42]  S. Bertenshaw,et al.  (R)-2-(4-Phenylbutyl)dihydrobenzofuran derivatives as melatoninergic agents. , 2005, Bioorganic & medicinal chemistry letters.

[43]  R. Mattson,et al.  Indanyl piperazines as melatonergic MT2 selective agents. , 2003, Bioorganic & medicinal chemistry letters.

[44]  N. Raikhlin,et al.  Melatonin and enterochromaffine cells. , 1976, Acta histochemica.

[45]  R. Reiter.  The pineal and its hormones in the control of reproduction in mammals. , 1980, Endocrine reviews.

[46]  P. Lavie,et al.  Nocturnal melatonin onset is phase locked to the primary sleep gate. , 1997, The American journal of physiology.

[47]  J. Nicolas,et al.  Synthesis of phenalene and acenaphthene derivatives as new conformationally restricted ligands for melatonin receptors. , 2000, Journal of medicinal chemistry.

[48]  M. Dubocovich,et al.  Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[49]  H. Manev,et al.  The pattern of melatonin receptor expression in the brain may influence antidepressant treatment. , 2007, Medical hypotheses.

[50]  D. Sugden,et al.  Mapping the melatonin receptor. 3. Design and synthesis of melatonin agonists and antagonists derived from 2-phenyltryptamines. , 1995, Journal of medicinal chemistry.

[51]  M. Polymeropoulos,et al.  Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials , 2009, The Lancet.

[52]  M. Menaker,et al.  The clock in the mouse retina: melatonin synthesis and photoreceptor degeneration , 1998, Brain Research.

[53]  G. Benítez-King,et al.  Binding of 3H-melatonin to calmodulin. , 1993, Life sciences.

[54]  C. D. Mahle,et al.  N‐{2‐[2‐(4‐Phenylbutyl)benzofuran‐4‐yl]cyclopropylmethyl}acetamide: An Orally Bioavailable Melatonin Receptor Agonist. , 2005 .

[55]  N. Rogers,et al.  Melatonin and Melatonin Analogues , 2009 .

[56]  D. Sugden,et al.  Binding affinity and biological activity of oxygen and sulfur isosteres at melatonin receptors as a function of their hydrogen bonding capability. , 2004, Bioorganic chemistry.

[57]  N. Sarbin,et al.  4-Substituted anilides as selective melatonin MT2 receptor agonists. , 2004, Bioorganic & medicinal chemistry letters.

[58]  G. Maestroni.  The immunotherapeutic potential of melatonin , 2001, Expert opinion on investigational drugs.

[59]  J. Boutin,et al.  Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands. , 2010, Bioorganic & medicinal chemistry.

[60]  Josep M. Guerrero,et al.  Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  M. Hastings,et al.  Rhythmic gene expression in pituitary depends on heterologous sensitization by the neurohormone melatonin , 2002, Nature Neuroscience.

[62]  R. Tokuyama,et al.  Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo , 2007, Journal of pineal research.

[63]  R. Hardeland.  Melatonin: Signaling mechanisms of a pleiotropic agent , 2009, BioFactors.

[64]  Y. Wong,et al.  Synthesis of Substituted N‐[3‐(3‐Methoxyphenyl)propyl] Amides as Highly Potent MT2‐Selective Melatonin Ligands. , 2010 .

[65]  T. Thalhammer,et al.  The melatonin receptor subtype MT2 is present in the human cardiovascular system , 2003, Journal of pineal research.

[66]  D. Cardinali,et al.  Metabolism of serotonin by the rat retina in vitro , 1971, Journal of neurochemistry.

[67]  A. Cagnacci,et al.  Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. , 1999, The American journal of cardiology.

[68]  F. Boeckler,et al.  Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: Synthesis, biological evaluation, and molecular modeling of the putative bioactive conformation. , 2006, Bioorganic & medicinal chemistry.